Evidence map›Paper›PMID 40993967›Full record

Trial reportHelicobacter

Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults.

Stefano Bibbò, Gustav Ahlström, Giovanni Mario Pes, David Y Graham, Lars Engstrand, Elettra Merola, Maria Pina Dore

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Helicobacter. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03404440 (Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Combination), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03404440 nacompletednot on this map

Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Combination (Strains DSM 17938 and ATCC PTA 6475) and a Proton Pump Inhibitor

TypeinterventionalSponsorUniversity of BariRan2016 to 2017Enrolled56ConditionsHelicobacter Pylori InfectionArmsL.Reuteri
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Stefano BibbòDepartment of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Gustav AhlströmCentre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden.
Giovanni Mario PesDepartment of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.ORCID https://orcid.org/0000-0003-3265-2823
David Y GrahamBaylor College of Medicine, Houston, Texas, USA.
Lars EngstrandCentre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Solna, Sweden.
Elettra MerolaDepartment of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Maria Pina DoreDepartment of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.ORCID https://orcid.org/0000-0001-7305-3531

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori eradication therapy typically consists of a combination of antibiotics and an antisecretory drug. Probiotics may be added to reduce side effects and possibly improve outcomes. MATERIALS AND

methodsWe conducted a double-blind, randomized trial of pantoprazole plus either Lactobacillus reuteri (Gastrus) (high dose) or a matching placebo to assess the impact on the gut microbiota of H. pylori-positive adults. Fecal samples were collected at baseline and after one and 2 months for shotgun metagenomic sequencing.

resultsA total of 26 patients were recruited and completed therapy. L. reuteri was only detected in the group that received supplemental L. reuteri and only at the 1-month post-treatment interval. L. reuteri failed to colonize for long-term the gut, and challenge with L. reuteri failed to alter alpha-diversity (Shannon index) or beta-diversity (community ordination) metrics at any time point. Machine learning (PLS-DA) analysis identified the presence of L. reuteri as the most distinguishing feature at 1 month. No other taxa showed a significant difference between groups.

conclusionShort-term administration of pantoprazole and L. reuteri had no lasting effects on gut microbial composition. While L. reuteri transiently bloomed during supplementation, the overall gut microbiota showed resilience, returning to baseline shortly after therapy.

trial registrationIdentifier: NCT03404440.

Indexed as

Gastrointestinal MicrobiomeHelicobacter InfectionsLimosilactobacillus reuteriProbioticsProton Pump InhibitorsAdultAgedDouble-Blind MethodFecesFemaleHelicobacter pyloriHumansMaleMiddle AgedPantoprazolePantoprazoleProton Pump Inhibitorsgut microbiotaHelicobacter pyloriLactobacillus reuteriprobioticsproton pump inhibitors

Identifiers

PMID40993967
PMCPMC12460962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.